Embecta Corp. (NASDAQ: EMBC) shares soared 5.25% in pre-market trading on Friday following the release of its second-quarter fiscal 2025 financial results, which significantly exceeded analyst expectations.

The diabetes care company reported adjusted earnings per share of $0.70, surpassing the analyst consensus estimate of $0.53 by 32.08%. This represents a 4.48% increase from the same period last year. Embecta's quarterly revenue came in at $259 million, beating the analyst estimate of $253.94 million by 1.99%, despite a 9.82% decrease from the previous year.

Investors were particularly impressed by Embecta's profitability metrics. The company reported an adjusted EBITDA of $97.1 million, significantly higher than the IBES estimate of $83.7 million. Additionally, adjusted operating income reached $81.4 million, compared to the expected $66.6 million. These strong results, coupled with the company's maintenance of its full-year adjusted earnings per share guidance despite lowered revenue expectations, have boosted investor confidence in Embecta's ability to navigate challenges in the current market environment.